Recent studies suggest that high expression of the pro-inflammatory cytokine interleukin-6 (IL-6) is associated with poor survival of lung cancer patients. Accordingly, IL-6 has been a target of great interest for lung cancer therapy. However, the role of IL-6 in lung cancer has not been determined yet.
Introduction
Lung cancer is the leading cause of cancer deaths in both women and men, responsible for roughly 160,000 deaths annually in the United States alone (1) . Moreover, approximately 85% of the patients with lung cancer die of the disease within 5 years (1) . A better understanding of the mechanisms underlying lung cancer development and progression and therapy resistance is direly needed to design novel effective therapies for this deadliest cancer. The most predominant risk factor for lung cancer is tobacco smoking, which accounts for about 87% of lung cancer cases (2) . Tobacco smoke induces genetic alterations, particularly activating mutations of the K-Ras oncogene, in lung epithelium to initiate and promote carcinogenesis (2) .
One of the important functions of K-Ras activation is to induce expression of interleukin-6 (IL-6), a pleiotropic pro-inflammatory cytokine that has been suggested to function as a lynchpin between inflammation and cancer in several cancers, such as colon and liver cancers (3, 4) . Indeed, IL-6 is expressed in over 50% of human lung cancer cell lines and primary tissues (5, 6) . As a matter of fact, IL-6 can be detected in serum, pleural fluids, bronchioalveolar lavage fluids (BALF) and breath condensate of patients with lung cancer (6) (7) (8) (9) (10) . More importantly, high IL-6 level in tumor tissue, serum, BALF and breath condensate is associated with lung cancer progression, resistance to antitumor therapies, and poor survival of lung cancer patients (6) (7) (8) (9) (10) . Moreover, high IL-6 level is also associated with postoperative complication and postoperative recurrence of lung cancer (11) (12) (13) .
Mechanistic studies suggest that IL-6 promotes lung cancer cell proliferation and migration through activation of the transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) (4, 7, 14) . In line with the role of IL-6 in STAT3 activation, STAT3 has been found to be persistently activated in up to 65% of human lung cancers (4, 14) . Also, the constitutive activation of STAT3 is associated with lung cancer progression, therapy resistance, and poor survival of lung cancer patients (4, 14) . These studies suggest a molecular link between IL-6 and lung cancer.
Research. However, it remains unknown whether and how IL-6 is involved in the initiation of lung cancer.
Current studies on lung cancer mainly focus on the role of IL-6 in the in vitro growth in cell culture and in vivo growth in immunodeficient mice of lung cancer cell lines (5, 15) . Although useful, these studies require validation in endogenously arising lung tumors. They cannot address the role of IL-6 in the early stages of lung tumorigenesis. Furthermore, they cannot determine whether and how the inflammation-regulatory activity of IL-6 is involved in lung cancer, because the hosts they used for the in vivo growth of lung cancer cells lack immune responses and immunity. Another important issue that still remains to be determined is the role of IL-6 in lung physiology under oncogenic stresses.
Addressing these issues is of importance and interest, given the pleiotropic and complex functions of IL-6. In particular, using endogenous lung tumorigenesis in immune-competent mice as a model system we have recently found that STAT3 plays opposing roles in the initiation and progression of lung tumor (16) . Accordingly, we also examined the effect of IL-6 deficiency on the initiation and development of endogenous lung tumor in immune-competent mice. 
Materials and Methods

Animals
BALF and immunofluorescence (IF) assays
Mice were sacrificed, and their lungs were lavaged four times with phosphate buffered saline (PBS). The recovered BALF were centrifuged. Cells from BALF were visualized by Hema 3 staining, and different leukocytes were counted. Cells from BALF were also subjected to IF assays as described previously (17) . The antibodies used for IF staining were listed in Supplemental Table 1 .
Immunohistochemistry (IHC) assays
Mouse lungs were excised, fixed in formalin, embedded in paraffin, and cut into 4-μm-thick sections. Sections were subjected to IHC staining as described previously (16 
Real-time polymerase chain reaction (Real-time PCR) analysis
Mouse lung tissues, lung tumor tissues, BAL cells or lung epithelial cells were subjected to RNA extraction, RNA reverse transcription and real-time PCR as described previously (16) . Primer pairs used for real-time PCR were listed in the Supplemental Table 2 .
Statistical Analysis
Data were reported as mean ± standard deviation (SD). The Student's t test (two tailed) was used to assess significance of differences between two groups, and p values < 0.05 and 0.01 were considered statistically significant and highly statistically significant, respectively (16) . Figure 2D ).
Results
IL-6
In line with in vivo data, addition of IL-6 prevented iNOS induction in macrophages in vitro ( Figure   S2 ). These data suggested that IL-6 suppresses iNOS expression in lung macrophages. In contrast, lung macrophages in IL-6 Δ/Δ mice almost completely lost the ability to express IL-10, although Figure 2D ). Nevertheless, this data is highly consistent with the finding that lung macrophages in IL-6 Altogether, these data suggested that the IL-6/STAT3 signaling plays opposite roles in the initiation and growth of lung cancer.
Discussion
IL-6 is a target of great interest for the prevention and treatment of human lung and other cancers (18) , concomitant with an appreciation for the critical role of IL-6 in cancer cell growth and the association of high IL-6 expression with cancer progression and poor survival of cancer patients (4). In addition, the enthusiasm also comes from clinical trial studies showing that IL-6-based therapies are particularly effective and tolerably safe for several inflammation diseases, such as rheumatoid arthritis, systemic juvenile idiopathic arthritis and Castleman's disease (19) . Our findings identify a complex role for IL-6 in lung cancer, preventing tumor induction while enhancing tumor growth (Figures 1 and   4 ). In line with our findings, recent studies indicate that high IL-6 expression is not associated with lung cancer risk in humans (20) , although it is associated with lung cancer progression and poor survival of lung cancer patients (6-10). It should be pointed out that even complete deletion of IL-6 can only delay lung cancer growth. Thus, to target IL-6 for lung cancer therapy, we need, on one hand, to consider the potential risk in increasing lung damage and tumorigenesis due to long-term IL-6
Research. 
outcomes. In this regard, recent Phase I and II clinical trials involving 125 lung cancer patients indicate that IL-6-targeted therapy alone has no obvious clinical benefits, except for an amelioration of lung cancer-associated anemia and cachexia in patients (19) . Although more careful and more lung cancer patients-involved clinical trials are needed to determine the clinical outcomes of IL-6-targeted therapy, it could be speculated that the overall clinical benefits of IL-6 therapy alone might be limited, giving both the tumor-suppressing and -promoting roles of IL-6 in lung cancer.
Interestingly, both lung tumor-suppressing and -promoting functions of IL-6 involve its ability in activating STAT3. IL-6 suppresses lung cancer induction through maintaining lung homeostasis and inducing tumor cell killing in STAT3-dependent manners. In addition to inducing STAT3 activation in lung epithelial cells, IL-6 activates STAT3 in other cells in lungs, particularly macrophages, to express IL-10, which serves as a paracrine stimulus to further enhance lung epithelial STAT3 activation for lung homeostasis under oncogenic stress (Figures 2 and S3 ). IL-6 also suppresses lung macrophages to express iNOS and thereby prevents iNOS-induced lung damage (Figures 2 and S2 ). IL-10 produced by lung macrophages, perhaps together with IL-6, also induces STAT3 activation in cytotoxic CD8 T cells for their survival and activation, which in turn induce tumor cell apoptosis (Figures 3 and S4) .
Thus, it seems that IL-6 utilizes multiple related mechanisms to suppress lung cancer initiation.
Paradoxically, IL-6 contributes to lung cancer growth also through STAT3-dependent mechanism. In this case, IL-6 activates STAT3 to induce Cyclin D1 in lung cancer cells, therefore promoting cancer proliferation (Figures 4 and S5) . In further support of these findings, our recent studies indicate that mice selectively deficient in lung epithelial STAT3 show overall similar phenotypes as IL-6 deficient mice in K-Ras-induced lung damage, tumor initiation and progression (16) .
In summary, these data demonstrate that the IL-6/STAT3 signaling plays overall opposite roles in the initiation and growth of lung cancer: it prevents lung cancer initiation through maintaining lung 13 homeostasis and inducing cytotoxic CD8 T cells, whereas contributing to (although it is not absolutely required for) lung cancer growth through inducing expression of key regulators of cell proliferation.
These studies not only greatly improve our understanding of the pathophysiologic actions of IL-6/STAT3 signaling and the pathogenesis of lung and other cancers associated with IL-6/STAT3 signaling, but also provide a mechanistic basis for targeting IL-6/STAT3 signaling to treat IL-6-and STAT3-associated cancers.
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